PharmAust Limited (PAA.AX)
AUD 0.23
(6.98%)
AUD 0.23
(6.98%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -6.65 Million AUD | -83.81% |
| 2023 | -3.62 Million AUD | -31.77% |
| 2022 | -2.74 Million AUD | 1.45% |
| 2021 | -2.78 Million AUD | -28.5% |
| 2020 | -2.17 Million AUD | -42.72% |
| 2019 | -1.52 Million AUD | 39.88% |
| 2018 | -2.53 Million AUD | -93.12% |
| 2017 | -1.31 Million AUD | 29.28% |
| 2016 | -1.85 Million AUD | 5.98% |
| 2015 | -1.97 Million AUD | -42.47% |
| 2014 | -1.38 Million AUD | -124.42% |
| 2013 | -616.21 Thousand AUD | 85.42% |
| 2012 | -4.22 Million AUD | 27.57% |
| 2011 | -5.83 Million AUD | -821.02% |
| 2010 | -633.76 Thousand AUD | -1.84% |
| 2009 | -622.3 Thousand AUD | 75.74% |
| 2008 | -2.56 Million AUD | 59.3% |
| 2007 | -6.3 Million AUD | -90.09% |
| 2006 | -3.31 Million AUD | -82.45% |
| 2005 | -1.81 Million AUD | -83.02% |
| 2004 | -992.87 Thousand AUD | 49.71% |
| 2003 | -1.97 Million AUD | 47.0% |
| 2002 | -3.72 Million AUD | -1385.82% |
| 2001 | -250.67 Thousand AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -6.65 Million AUD | -83.81% |
| 2024 Q2 | -2.46 Million AUD | 0.0% |
| 2024 Q4 | -4.19 Million AUD | 0.0% |
| 2023 Q4 | -2.64 Million AUD | 0.0% |
| 2023 FY | -3.62 Million AUD | -31.77% |
| 2023 Q2 | -974.59 Thousand AUD | 0.0% |
| 2022 FY | -2.74 Million AUD | 1.45% |
| 2022 Q4 | -1.52 Million AUD | 0.0% |
| 2022 Q2 | -1.22 Million AUD | 0.0% |
| 2021 FY | -2.78 Million AUD | -28.5% |
| 2021 Q2 | -1.46 Million AUD | 0.0% |
| 2021 Q4 | -1.32 Million AUD | 0.0% |
| 2020 Q2 | -1.13 Million AUD | 0.0% |
| 2020 FY | -2.17 Million AUD | -42.72% |
| 2020 Q4 | -1.04 Million AUD | 0.0% |
| 2019 FY | -1.52 Million AUD | 39.88% |
| 2019 Q2 | -71.93 Thousand AUD | 0.0% |
| 2019 Q4 | -1.45 Million AUD | 0.0% |
| 2018 Q2 | -1.49 Million AUD | 0.0% |
| 2018 FY | -2.53 Million AUD | -93.12% |
| 2018 Q4 | -1.03 Million AUD | 0.0% |
| 2017 Q4 | -930.86 Thousand AUD | 0.0% |
| 2017 Q2 | -379.29 Thousand AUD | 0.0% |
| 2017 FY | -1.31 Million AUD | 29.28% |
| 2016 Q4 | -908.11 Thousand AUD | 0.0% |
| 2016 Q2 | -944.38 Thousand AUD | 0.0% |
| 2016 FY | -1.85 Million AUD | 5.98% |
| 2015 FY | -1.97 Million AUD | -42.47% |
| 2015 Q4 | -898.64 Thousand AUD | 0.0% |
| 2015 Q2 | -1.07 Million AUD | 0.0% |
| 2014 Q2 | -639.09 Thousand AUD | -314.86% |
| 2014 Q1 | -154.05 Thousand AUD | 0.0% |
| 2014 FY | -1.38 Million AUD | -124.42% |
| 2014 Q4 | -743.78 Thousand AUD | 0.0% |
| 2013 Q2 | -296.46 Thousand AUD | 71.95% |
| 2013 Q3 | -154.05 Thousand AUD | 48.04% |
| 2013 Q1 | -1.05 Million AUD | 0.0% |
| 2013 Q4 | -154.05 Thousand AUD | 0.0% |
| 2013 FY | -616.21 Thousand AUD | 85.42% |
| 2012 FY | -4.22 Million AUD | 27.57% |
| 2012 Q4 | -1.05 Million AUD | 0.0% |
| 2012 Q3 | -1.05 Million AUD | 0.0% |
| 2012 Q2 | -1.05 Million AUD | 27.57% |
| 2012 Q1 | -1.45 Million AUD | 0.0% |
| 2011 FY | -5.83 Million AUD | -821.02% |
| 2011 Q4 | -1.45 Million AUD | 0.0% |
| 2011 Q1 | -158.44 Thousand AUD | 0.0% |
| 2011 Q2 | -1.45 Million AUD | -821.02% |
| 2011 Q3 | -1.45 Million AUD | 0.0% |
| 2010 Q2 | -158.44 Thousand AUD | -1.84% |
| 2010 FY | -633.76 Thousand AUD | -1.84% |
| 2010 Q1 | -155.57 Thousand AUD | 0.0% |
| 2010 Q4 | -158.44 Thousand AUD | 0.0% |
| 2010 Q3 | -158.44 Thousand AUD | 0.0% |
| 2009 FY | -622.3 Thousand AUD | 75.74% |
| 2009 Q1 | -641.27 Thousand AUD | 0.0% |
| 2009 Q2 | -155.57 Thousand AUD | 75.74% |
| 2009 Q3 | -155.57 Thousand AUD | 0.0% |
| 2009 Q4 | -155.57 Thousand AUD | 0.0% |
| 2008 Q2 | -641.27 Thousand AUD | 59.3% |
| 2008 Q3 | -641.27 Thousand AUD | 0.0% |
| 2008 Q4 | -641.27 Thousand AUD | 0.0% |
| 2008 FY | -2.56 Million AUD | 59.3% |
| 2008 Q1 | -1.57 Million AUD | 0.0% |
| 2007 Q1 | -828.84 Thousand AUD | 0.0% |
| 2007 Q4 | -1.57 Million AUD | 0.0% |
| 2007 Q3 | -1.57 Million AUD | 0.0% |
| 2007 FY | -6.3 Million AUD | -90.09% |
| 2007 Q2 | -1.57 Million AUD | -90.09% |
| 2006 FY | -3.31 Million AUD | -82.45% |
| 2006 Q2 | -828.84 Thousand AUD | -82.45% |
| 2006 Q3 | -828.84 Thousand AUD | 0.0% |
| 2006 Q4 | -828.84 Thousand AUD | 0.0% |
| 2006 Q1 | -454.28 Thousand AUD | 0.0% |
| 2005 Q3 | -454.28 Thousand AUD | 0.0% |
| 2005 Q2 | -454.28 Thousand AUD | -83.02% |
| 2005 Q1 | -248.21 Thousand AUD | 0.0% |
| 2005 Q4 | -454.28 Thousand AUD | 0.0% |
| 2005 FY | -1.81 Million AUD | -83.02% |
| 2004 Q3 | -248.21 Thousand AUD | 0.0% |
| 2004 Q1 | -493.53 Thousand AUD | 0.0% |
| 2004 FY | -992.87 Thousand AUD | 49.71% |
| 2004 Q4 | -248.21 Thousand AUD | 0.0% |
| 2004 Q2 | -248.21 Thousand AUD | 49.71% |
| 2003 Q1 | -931.13 Thousand AUD | 0.0% |
| 2003 FY | -1.97 Million AUD | 47.0% |
| 2003 Q2 | -493.53 Thousand AUD | 47.0% |
| 2003 Q4 | -493.53 Thousand AUD | 0.0% |
| 2003 Q3 | -493.53 Thousand AUD | 0.0% |
| 2002 Q3 | -931.13 Thousand AUD | 0.0% |
| 2002 FY | -3.72 Million AUD | -1385.82% |
| 2002 Q4 | -931.13 Thousand AUD | 0.0% |
| 2002 Q2 | -931.13 Thousand AUD | -1385.82% |
| 2002 Q1 | -62.66 Thousand AUD | 0.0% |
| 2001 Q3 | -62.66 Thousand AUD | 0.0% |
| 2001 Q4 | -62.66 Thousand AUD | 0.0% |
| 2001 Q2 | -62.66 Thousand AUD | 0.0% |
| 2001 FY | -250.67 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 168.529% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -356.343% |
| Zelira Therapeutics Limited | -5.93 Million AUD | -12.132% |
| Biome Australia Limited | -1.91 Million AUD | -248.029% |
| Patrys Limited | -3.53 Million AUD | -88.142% |
| Orthocell Limited | -11.68 Million AUD | 42.997% |
| Imugene Limited | -140.93 Million AUD | 95.275% |
| Noxopharm Limited | -7.53 Million AUD | 11.631% |
| PYC Therapeutics Limited | -38.85 Million AUD | 82.864% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 45.907% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 7.344% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 7.922% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 24.402% |
| CSL Limited | 5.64 Billion AUD | 100.118% |
| Arovella Therapeutics Limited | -7.19 Million AUD | 7.43% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -117.427% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 113.548% |
| Starpharma Holdings Limited | -15.15 Million AUD | 56.075% |
| Nanollose Limited | -1.24 Million AUD | -432.765% |
| Memphasys Limited | -2.7 Million AUD | -146.251% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -212.08% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -223.775% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -50.478% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 54.703% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -131.703% |
| Race Oncology Limited | -13.38 Million AUD | 50.237% |
| Nyrada Inc. | -4.56 Million AUD | -46.012% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | 73.429% |
| Immutep Limited | -44.93 Million AUD | 85.182% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 85.137% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 66.03% |
| BTC Health Limited | 1.05 Million AUD | 730.978% |
| Acrux Limited | -9.83 Million AUD | 32.29% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 102.947% |
| Biotron Limited | -5.15 Million AUD | -29.264% |
| Tissue Repair Ltd | -4.87 Million AUD | -36.561% |
| AdAlta Limited | -5.26 Million AUD | -26.552% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 85.896% |
| Hexima Limited | -1 Million AUD | -560.087% |
| AnteoTech Limited | -11.72 Million AUD | 43.218% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 89.774% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 69.804% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -45.094% |
| Actinogen Medical Limited | -12.83 Million AUD | 48.137% |
| Immuron Limited | -5.8 Million AUD | -14.782% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -17.411% |